July 25-27 2017

The Hyatt Regency, Boston, MA

Speaker Line-Up

Expand/Collapse

Emmett Cunningham
Managing Director
Clarus Ventures

Day Two

Thursday July 27, 2017

15:30 | Interactive Panel: How Do Investors View This Space?

08:45 | Chair's Opening Remarks

Mitchell de Long
Vice President, Chemistry
Aerie Pharmaceuticals

Day One

Wednesday July 26, 2017

14:00 | Setting & Ruthlessly Enforcing Initial Success Criteria To Minimize Late-Stage Developmental Failures

Cheryl Rowe-Rendleman
Owner and Chief Clinical Consultant
Omar Consulting

Workshop A

Tuesday July 25th 2017

09:00 |
Interactive Panel-Based Workshop – What Does It Take To Succeed In This Space?

Jason Ehrlich
Global Head of Clinical Ophthalmology & Senior Group Medical Director
Genentech

Day Two

Thursday July 27, 2017

13:00 | Select Appropriate Endpoints For Ophthalmic Clinical Trials

09:00 | Future Strategies to Enhance Ophthalmic Drug Delivery

Canwen Jiang
Therapeutic Area Head, Global Ophthalmology Development Franchise
Novartis

Day One

Wednesday July 26, 2017

13:30 | Establishing Effective Clinical Development Strategies From The Outset

Melissa Liew
Vice President, Therapeutic Area Head, Ophthalmology
Novartis

Day Two

Thursday July 27, 2017

11:30 | Establishing A Rapid Yet Robust Clinical Path To Phase III

T. Michael Nork
Associate Professor, Ophthalmology
University of Wisconsin

Day One

Wednesday July 26, 2017

15:30 | Harnessing University-Based Expertise to Benefit Ocular Drug Development

Maria Mirotsou
Senior Director of Research
Astellas Institute for Regenerative Medicine

Day One

Wednesday July 26, 2017

09:30 | Interactive Panel Discussion – Pioneering Gene & Stem Cell Therapies In Ophthalmology

09:15 | Overcoming The Challenges Of Stem Cell-Based Therapies

Ram Palanki
Vice President, Strategic Marketing & Sales
Santen

Day Two

Thursday July 27, 2017

15:30 | Interactive Panel: How Do Investors View This Space?

Rajendra Kumar-Singh
Co-Founder & Vice President
Hemera Bioscience

Day One

Wednesday July 26, 2017

15:00 | Pioneering a Gene Therapy Approach for Dry-AMD: From Concept through to Clinical Development

Stephen Poor
Senior Investigator II
Novartis

Day One

Wednesday July 26, 2017

11:30 | Translatability Pitfalls Of Preclinical Models of Macular Degeneration

Michael Young
Associate Professor of Ophthalmology
Harvard Medical School

Day One

Wednesday July 26, 2017

09:30 | Interactive Panel Discussion – Pioneering Gene & Stem Cell Therapies In Ophthalmology

09:00 | What Is The True Potential Of Gene & Stem Cell-Based Therapeutics In Ophthalmology?

Naj Sharif
Executive Director & Head, Global Alliances & External Research
Santen

Day One

Wednesday July 26, 2017

17:00 | Chair's Closing Remarks & End of Conference Day One

08:45 | Chair's Opening Remarks

Day Two

Thursday July 27, 2017

13:30 | Improving On The Standard of Care – Role Of Combination Products?

Glenn Noronha
Chief Scientific Officer
Clearside Biomedical

Day One

Wednesday July 26, 2017

12:00 | What Does ‘Proof of Concept’ Actually Mean?

Mitchell Brigell
Vice President, Clinical Development
Aerpio Therapeutics

Day Two

Thursday July 27, 2017

11:00 | Optimizing Clinical Trial Recruitment & Enrolment

Leonide Saad
President and CEO
Alkeus Pharmaceuticals

Day Two

Thursday July 27, 2017

15:00 | Operational Decision Making – Avoiding Late-Stage Pitfalls

Tomas Navratil
Senior Vice President, Development
Envisia Therapeutics

Day Two

Thursday July 27, 2017

09:15 | Technical Insights Into Sustained Drug Delivery Approaches

Cadmus Rich
Vice President, Medical Affairs and Clinical Development
Inotek Pharmaceuticals

Day Two

Thursday July 27, 2017

14:30 | Improving Interactions With CROs Throughout The Drug Development Process

Shazia Ahmad
Director, Patient & Physician Services
UBC - An Express Scripts Company

Workshop B

Tuesday July 25th 2017

13:00 |
Leveraging successful strategies in patient recruitment & retention

Abraham Scaria
Vice President, Ophthalmology
Casebia Therapeutics

Day One

Wednesday July 26, 2017

09:30 | Interactive Panel Discussion – Pioneering Gene & Stem Cell Therapies In Ophthalmology